>

MEETINGS / EVENTS

RSS

November 08 - 09 2014, 12:00 AM - 12:00 AM

ASA Quality Meeting 2014

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

>

FDA MEDWATCH ALERTS

October 20, 2014

Lidocaine HCI Injection, USP 10 MG Per ML, 30 ML Single-Dose, Preservative-Free, by Hospira: Recall - Particulate Matter

Summary:

FDA Medwatch Alert 10-20-14

October 16, 2014

FDA MedWatch - LifeCare Flexible Intravenous Solutions by Hospira, Inc.: Recall - Potential for Leakage

Summary:

FDA MedWatch LifeCare Flexible Intravenous Solutions by Hospira Inc

October 13, 2014

FDA MedWatch - CareFusion EnVe and ReVel Ventilators: Class 1 Recall - Power Connection Failure

Summary:

FDA MedWatch CareFusion EnVe and ReVel Ventilators

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

FDA Alerts and Recalls

AUDIENCE: Surgery, Anesthesia, Neurology, Healthcare Professionals

ISSUE: FDA has observed fungal contamination by direct microscopic examination of foreign matter taken from a sealed vial of methylprednisolone acetate collected from New England Compounding Center (NECC). FDA is in the process of conducting additional microbial testing to confirm the exact species of the fungus.

Investigation into the exact source of the outbreak is still ongoing, but the outbreak is associated with a potentially contaminated medication. That product is preservative-free methylprednisolone acetate (80mg/ml), an injectable steroid produced and distributed by New England Compounding Center (NECC) in Framingham, Massachusetts. CDC’s interim data show that all infected patients received injection with this product.

BACKGROUND: FDA was been working closely with CDC, several state health departments, and the Massachusetts Board of Pharmacy to investigate the scope and cause of the outbreak of fungal meningitis. FDA inspectors in the New England District Office, in cooperation with the Massachusetts Board of Registration in Pharmacy have been conducting an inspection of the New England Compounding Center. The firm voluntarily ceased all operations and surrendered its license to the Massachusetts Board of Registration in Pharmacy on October 3, 2012.

RECOMMENDATION: Out of an abundance of caution, FDA is taking the additional step of recommending that health care professionals and consumers not use any product that was produced by NECC at this time. In addition, FDA requests that health care professionals retain and secure all remaining products purchased from NECC until FDA provides further instructions regarding the disposition of these products.

Although the investigation into the source of the outbreak is still ongoing, if you have purchased a product from NECC, FDA is advising not to use it at this time. This includes all products compounded and distributed at NECC; not just the ones that have been recalled. Please see the CDC website for additional information.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

Complete and submit the report Online: www.fda.gov/MedWatch/report.htm

 

Download form

or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Read the MedWatch safety alert, incliding links to the FDA statement, Q&As, and list of recalled products, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm322849.htm


You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm

Follow MedWatch on Twitter

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

Alerts By Date

81–100 of 147 results
Show:

Monday, January 07, 2013

Fisher and Paykel Healthcare Reusable Breathing Circuit Class I Recall - Pinholes in Tubes

Fisher and Paykel Healthcare Reusable Breathing Circuit Class I Recall - Pinholes in Tubes

view details »

Friday, November 30, 2012

Mindray A3 and A5 Anesthesia Delivery System: Class I Recall - Gasket Leak

Mindray A3 and A5 Anesthesia Delivery System

view details »

Friday, November 09, 2012

Baxter Healthcare Corp. Buretrol Solution Sets: Class 1 Recall - May Not Function as Expected

Baxter Healthcare Corp Buretrol Solution Sets

view details »

Thursday, November 01, 2012

Fungal Meningitis Outbreak Laboratory results from samples of two additional recalled NECC products

Fungal Meningitis Outbreak Laboratory results from samples of two additional recalled NECC products

view details »

Monday, October 22, 2012

Fungal Meningitis Outbreak: FDA Provides NECC Customer List

Fungal Meningitis Outbreak FDA Provides NECC Customer List

view details »

Thursday, October 18, 2012

FDA Statement on Fungal Meningitis Outbreak: Additional Patient Notification Advised - Update

FDA Statement on Fungal Meningitis Outbreak Additional Patient Notification Advised Update

view details »

Monday, October 15, 2012

FDA Statement on Fungal Meningitis Outbreak: Additional Patient Notification Advised

FDA Statement on Fungal Meningitis Outbreak Additional Patient Notification Advised

view details »

Monday, October 08, 2012

New England Compounding Center (NECC): Potentially Contaminated Medication Fungal Meningitis Outbreak

New England Compounding Center Potentially Contaminated Medication Fungal Meningitis Outbreak

view details »

Friday, August 17, 2012

Hospira Hydromorphone Hydrochloride Injection

Hospira Hydromorphone Hydrochloride Injection

view details »